Codexis (CDXS) Liabilities and Shareholders Equity (2010 - 2026)
Codexis (CDXS) posted quarterly Liabilities and Shareholders Equity of $129.4 million for Q1 2026, little changed year-over-year from $128.9 million in Q1 2025, and down 12.47% quarter-over-quarter from $147.8 million in Q4 2025.
Codexis (CDXS) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Codexis' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $129.4 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity changed 0.37% year-over-year to $129.4 million; the TTM figure through Mar 2026 stood at $539.4 million (down 3.35% YoY), while the FY2025 annual figure was $147.8 million, down 0.81% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $129.4 million, down from $147.8 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $250.4 million in Q4 2022, with the low at $124.0 million in Q3 2025.
- The 5-year median for Liabilities and Shareholders Equity is $149.0 million (2024), against an average of $171.7 million.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity rose 10.89% in 2022, then slumped 45.46% in 2023.
- Codexis' Liabilities and Shareholders Equity stood at $250.4 million in 2022, then plunged by 45.46% to $136.6 million in 2023, then climbed by 9.12% to $149.0 million in 2024, then fell by 0.81% to $147.8 million in 2025, then decreased by 12.47% to $129.4 million in 2026.
- Business Quant data shows CDXS's Liabilities and Shareholders Equity at $129.4 million in Q1 2026, $147.8 million in Q4 2025, and $124.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Codexis | 152.06 Mn | 97.14 Mn | 11.40 Mn | 120.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 120.06 Mn |
| Mar 31, 2026 | 129.37 Mn |
| Dec 31, 2025 | 147.80 Mn |
| Sep 30, 2025 | 123.96 Mn |
| Jun 30, 2025 | 138.25 Mn |
| Mar 31, 2025 | 128.89 Mn |
| Dec 31, 2024 | 149.01 Mn |
| Sep 30, 2024 | 148.18 Mn |
| Jun 30, 2024 | 132.01 Mn |
| Mar 31, 2024 | 149.56 Mn |
| Dec 31, 2023 | 136.56 Mn |
| Sep 30, 2023 | 154.46 Mn |
| Jun 30, 2023 | 206.76 Mn |
| Mar 31, 2023 | 218.07 Mn |
| Dec 31, 2022 | 250.39 Mn |
| Sep 30, 2022 | 235.29 Mn |
| Jun 30, 2022 | 234.97 Mn |
| Mar 31, 2022 | 235.27 Mn |
| Dec 31, 2021 | 246.38 Mn |
| Sep 30, 2021 | 227.55 Mn |